Story perspectives

Novartis to Acquire Tourmaline Bio for $1.4 Billion

9/9/2025

Summary

Story summary

Novartis will acquire Tourmaline Bio for about $1.4 billion, offering $48 per share, a 59% premium.
The focus is on pacibekitug, an anti-IL-6 monoclonal antibody for systemic inflammation in atherosclerotic cardiovascular disease.
Phase II trials show pacibekitug significantly reduces inflammation markers with a favorable safety profile.
The deal is set to close in Q4 2025, pending regulatory approvals.
This acquisition enhances Novartis' cardiovascular portfolio and addresses unmet medical needs.

History

Historical Context

In 2015, the FDA approved the first monoclonal antibody for rheumatoid arthritis, a milestone in biologic therapies. Novartis, under CEO Vasant Narasimhan, is acquiring Tourmaline Bio for $1.4 billion to enhance its portfolio with pacibekitug, targeting systemic inflammation. This acquisition aligns with the pharmaceutical industry's trend to address unmet medical needs, particularly in cardiovascular diseases, potentially improving treatment options for patients.

1 of 2

Story summary

Novartis will acquire Tourmaline Bio for about $1.4 billion, offering $48 per share, a 59% premium.
The focus is on pacibekitug, an anti-IL-6 monoclonal antibody for systemic inflammation in atherosclerotic cardiovascular disease.
Phase II trials show pacibekitug significantly reduces inflammation markers with a favorable safety profile.
The deal is set to close in Q4 2025, pending regulatory approvals.
This acquisition enhances Novartis' cardiovascular portfolio and addresses unmet medical needs.

1 / 2